Klinische Studie – Psoriasis und Psoriatische Arthritis (Clinical Trial – Germany)

Zur Studie

with superior selectivity and specificity

Therapeutic peptides

toxins of venomous animals

Derived from evolutionary tuned

which selectively

Peptide drugs

target ion channels

for autoimmune patients

Improving quality of life

Targeting Ion Channels

MORE

si-544 – A Highly Differentiated Asset in Autoimmunity

Best-in-class Kv1.3 blocker
Benchmark for safety and tolerability in autoimmune therapy
Maintains patient’s full immunocompetence
Short treatment course delivers sustained clinical benefit
Pipeline drug for autoimmunity

Our Goal

To improve quality of life for patients by developing best-in-class ion channel blockers.

A highly efficient screening and development platform to identify and optimize the most targeted peptides for our drug development.

Events

Meet selectION, Inc. at BIO International Convention in Boston,MA, on June 16^th-19^th, 2025

May 26, 2025

SAN DIEGO, May 26, 2025 – Meet selectION’s management team for an update on selectION’s best-in-class Kv1.3 ion channel blocker for the treatment of T-cell mediated autoimmunity while maintaining the patients’ full immunocompetence. selectION successfully completed its first-in-human study with…

Meet selectION, Inc. at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, CA, on January 13^th-16^th, 2025

December 11, 2024

SAN DIEGO, Dec 9, 2024 – Meet selectION’s management team for an update on selectION’s best-in-class Kv1.3 ion channel blocker for the treatment of T-cell mediated autoimmunity while maintaining the patients’ full immunocompetence. selectION successfully completed its first-in-human study with…

Klinische Studie – Psoriasis und Psoriatische Arthritis (Clinical Trial – Germany)

with superior selectivity and specificity

Therapeutic peptides

si-544 – A Highly Differentiated Asset in Autoimmunity

Best-in-class Kv1.3 blocker

Benchmark for safety and tolerability in autoimmune therapy

Maintains patient’s full immunocompetence

Short treatment course delivers sustained clinical benefit

Pipeline drug for autoimmunity

Our Goal

To improve quality of life for patients by developing best-in-class ion channel blockers.

Our Technology

A highly efficient screening and development platform to identify and optimize the most targeted peptides for our drug development.

News & Events

Meet selectION, Inc. at BIO International Convention in Boston,MA, on June 16^th-19^th, 2025

Meet selectION, Inc. at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, CA, on January 13^th-16^th, 2025

About

Recent News

Contact

Klinische Studie – Psoriasis und Psoriatische Arthritis (Clinical Trial – Germany)

with superior selectivity and specificity

Therapeutic peptides

si-544 – A Highly Differentiated Asset in Autoimmunity

Best-in-class Kv1.3 blocker

Benchmark for safety and tolerability in autoimmune therapy

Maintains patient’s full immunocompetence

Short treatment course delivers sustained clinical benefit

Pipeline drug for autoimmunity

Our Goal

To improve quality of life for patients by developing best-in-class ion channel blockers.

Our Technology

A highly efficient screening and development platform to identify and optimize the most targeted peptides for our drug development.

News & Events

Meet selectION, Inc. at BIO International Convention in Boston,MA, on June 16th-19th, 2025

Meet selectION, Inc. at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, CA, on January 13th-16th, 2025

About

Recent News

Contact

Meet selectION, Inc. at BIO International Convention in Boston,MA, on June 16^th-19^th, 2025

Meet selectION, Inc. at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, CA, on January 13^th-16^th, 2025